Clinical outcome and biomarker assessments of a multi-centre phase II trial assessing niraparib with or without dostarlimab in recurrent endometrial carcinoma.
Madariaga A, Garg S, Tchrakian N, Dhani NC, Jimenez W, Welch S, MacKay H, Ethier JL, Gilbert L, Li X, Rodriguez A, Chan L, Bowering V, Clarke B, Zhang T, King I, Downs G, Stockley T, Wang L, Udagani S, Oza AM, Lheureux S.
Madariaga A, et al. Among authors: chan l.
Nat Commun. 2023 Mar 15;14(1):1452. doi: 10.1038/s41467-023-37084-w.
Nat Commun. 2023.
PMID: 36922497
Free PMC article.
Clinical Trial.